Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / HEPA - Additional Phase IIa Data Confirms Hepion's CRV431 As A Very Promising NASH Candidate Drug

HEPA - Additional Phase IIa Data Confirms Hepion's CRV431 As A Very Promising NASH Candidate Drug

Hepion Pharmaceuticals Inc.
  • On September 13, Hepion Pharmaceuticals (NASDAQ:HEPA) reported additional data from phase IIa "AMBITION trial."
  • The main data reported by the company was the % reduction of the Pro-C3 biomarker in serum.
  • According to my estimate, CRV431 would be the candidate drug with the greatest reducing power of Pro-C3 over time.

For further details see:

Additional Phase IIa Data Confirms Hepion's CRV431 As A Very Promising NASH Candidate Drug
Stock Information
Company Name: Hepion Pharmaceuticals Inc.
Stock Symbol: HEPA
Market: NASDAQ
Website: hepionpharma.com
Menu
HEPA HEPA Quote HEPA Short HEPA News HEPA Articles HEPA Message Board
Get HEPA Alerts

News, Short Squeeze, Breakout and More Instantly...